Combining internal femoral shaft thickness with one or two textural parameters explained 72%-79% of failure load variance in the single-stance configuration and 63%-76% of failure load variance in the side-impact configuration.
Conclusion: In these excised femurs, combining find more textural parameters with cortical thickness measurements had a performance comparable to that of BMD alone in the explanation of femoral failure load. (C) RSNA, 2010″
The phase III AVAiL study evaluated the efficacy and safety
of the anti-vascular epidermal growth factor agent bevacizumab combined with platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC). We report the results of a preplanned analysis of Asian patients enrolled in AVAiL.
Patients with recurrent or advanced non-squamous NSCLC were randomized to receive
bevacizumab 7.5 mg/kg, bevacizumab 15 mg/kg or placebo, plus cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles, followed by bevacizumab or placebo until disease progression. An exploratory analysis was Z-IETD-FMK datasheet undertaken to assess efficacy and safety in an Asian subgroup.
Of the 1043 patients enrolled, 105 were Asian and were included in the subgroup analysis. Progression-free survival was 8.5 months (95% CI 7.3-10.8) in the bevacizumab 15-mg/kg group, 8.2 (95% CI 6.6-11.7) in the 7.5-mg/kg group and 6.1 (95% CI 5.1-8.0) in the placebo group. Median overall survival in the 7.5-mg/kg bevacizumab group was prolonged ASP2215 manufacturer compared with placebo group (HR 0.46; 95% CI 0.22-0.97). Nausea was the most common adverse event, occurring at similar rates (ranging from 69-76%) in all study groups. Hypertension was the most common adverse event of special interest, seen
in 29, 55 and 16% of patients in the 7.5-mg/kg and 15-mg/kg bevacizumab and placebo groups, respectively.
Study results strongly suggest that bevacizumab at a dose of 7.5 mg/kg improves the duration of overall survival when combined with cisplatin-gemcitabine in Asian patients. Bevacizumab was well tolerated in this patient group.”
“The modification of the defect mode in a one-dimensional (1D) photonic crystal (PC) in terahertz (THz) spectral region was systematically investigated by using THz time-domain spectroscopy (THz-TDS). The 1D PC was constructed by periodically arranging glass slides into an ordered structure. A defect was created by intentionally increasing the separation (i.e., the air gap) between two neighboring glass slides located in the middle of the PC. The tuning of the defect mode in the band gap was demonstrated by changing the thickness of the air gap. Modification of the defect mode was realized by inserting a silicon wafer into the defect. It was found that the appearance of the defect mode in the band gap depends not only on the relative position of the inserted silicon wafer with respect to the beam center but also on the resistivity of the silicon wafer.